|
**Overview**: Abortion Panel (Eczema Pediatric Panel)**Introduction**: The Abortion Panel (likely intended as Eczema Pediatric Panel based on parameters) is a diagnostic tool designed to screen for eczema allergens in children using serum samples. In India, pediatric atopic dermatitis affects 3-7 percent of children, with common triggers including milk, egg, wheat, and house dust mite. Sensitization is high in early childhood, but clinical allergy is lower, often leading to misattribution or unnecessary restrictions. Presents with intense itching, erythematous rash, dry skin, and recurrent flares impacting sleep and growth. High morbidity from underdiagnosis in rural and low-SES families, limited pediatric dermatology access, and overlap with infections. Per immunology practices (ICMR aligned), the test employs immunoassay for detailed parameter analysis over 1-2 days with high sensitivity/specificity, valuable for identifying triggers in refractory pediatric eczema. This diagnostic falls under pediatric allergy screening and targets children with suspected allergic eczema, addressing accurate detection to guide targeted avoidance and therapy. With morbidity elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications like secondary infections or growth delay. Its serum-based approach ensures reliable detection in pediatric settings.**Other Names**: Eczema Ped Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Expanded with specific IgE testing; in India, relevance with high pediatric eczema burden.**Purpose**: The test screens for 8 parameters including milk IgE to guide eczema assessment, identify key triggers, and inform treatment strategies in children.**Test Parameters**: 1. Total IgE, 2. Milk IgE, 3. Egg White IgE, 4. Wheat IgE, 5. Soy IgE, 6. Peanut IgE, 7. House Dust Mite IgE, 8. Codfish IgE.**Pretest Condition**: No fasting required; parents should report itching, rash, or flares in the child.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Parents should provide details on child's eczema onset, flare patterns, diet, family history of atopy, or environmental exposures.**Consent**: Written informed consent from parent/guardian is required, detailing the test's purpose, potential risks of untreated eczema including infections or sleep disturbance, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent skin infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible allergic triggers, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if flares persist.**Specialist Consultation**: Pediatric dermatologists or allergists should be consulted for case management, treatment planning, and coordination with child health programs.**Additional Supporting Tests**: Skin prick test, patch testing, or elimination diet trial for confirmation.**Test Limitations**: The test may produce false negatives in non-IgE mediated eczema or false positives in sensitization without clinical flare, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Indian Journal of Pediatrics 2024, Pediatric Dermatology Studies India 2023. |
